retatrutide phase 2 trial results Today, we shared new data from two 3 trials of retatrutide, our investigational triple agonist. Learn more: https://go.lilly.com/msrz1v retatrutide phase 2 obesity trial

Faster shipping, easier communication, clearer return processes, and reduced customs complications justify domestic sourcing preferences

Patients should contact a medical provider if they experience severe vomiting, dehydration, persistent abdominal pain, severe constipation, symptoms of gallbladder problems, or any concerning reaction

CagriSema , while promising, has underdelivered against the markets lofty expectations and now trails ZEPBOUND in real-world perception

Its about: Supporting your bodys natural fullness signals* Helping those signals last longer* Creating a steadier foundation for appetite and energy* Do you have more questions

Will retatrutide be available globally at launch

Its GLP-1 Patches are marketed as a simple, non-prescription way to support weight-loss goals without doctor visits or medications like Ozempic or Wegovy